Long-term Anticoagulation in a Patient With Severe Hemophilia A
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hemophilia A. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Report of a Clinical-biological Case: "Long-term Anticoagulation in a Patient With Severe Hemophilia A
Overview
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of \<1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.
Primary outcome measures
- FVIII Level [Time frame: Up to 15 months]
Eligibility criteria
Inclusion criteria
- Adult patient (≥ 18 years) with severe hemophilia A
- Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes.
Exclusion criteria
\- Subject having expressed objection to the reuse of their data for scientific research
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
France · 1 center
- Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France — Strasbourg
Identifiers
NCT: NCT07314983 · 9816